1
|
Khumukcham SS, Penugurti V, Bugide S, Dwivedi A, Kumari A, Kesavan PS, Kalali S, Mishra YG, Ramesh VA, Nagarajaram HA, Mazumder A, Manavathi B. HPIP and RUFY3 are noncanonical guanine nucleotide exchange factors of Rab5 to regulate endocytosis-coupled focal adhesion turnover. J Biol Chem 2023; 299:105311. [PMID: 37797694 PMCID: PMC10641178 DOI: 10.1016/j.jbc.2023.105311] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2023] [Revised: 09/01/2023] [Accepted: 09/15/2023] [Indexed: 10/07/2023] Open
Abstract
While the role of endocytosis in focal adhesion turnover-coupled cell migration has been established in addition to its conventional role in cellular functions, the molecular regulators and precise molecular mechanisms that underlie this process remain largely unknown. In this study, we report that proto-oncoprotein hematopoietic PBX-interacting protein (HPIP) localizes to focal adhesions as well as endosomal compartments along with RUN FYVE domain-containing protein 3 (RUFY3) and Rab5, an early endosomal protein. HPIP contains two coiled-coil domains (CC1 and CC2) that are necessary for its association with Rab5 and RUFY3 as CC domain double mutant, that is, mtHPIPΔCC1-2 failed to support it. Furthermore, we show that HPIP and RUFY3 activate Rab5 by serving as noncanonical guanine nucleotide exchange factors of Rab5. In support of this, either deletion of coiled-coil domains or silencing of HPIP or RUFY3 impairs Rab5 activation and Rab5-dependent cell migration. Mechanistic studies further revealed that loss of HPIP or RUFY3 expression severely impairs Rab5-mediated focal adhesion disassembly, FAK activation, fibronectin-associated-β1 integrin trafficking, and thus cell migration. Together, this study underscores the importance of HPIP and RUFY3 as noncanonical guanine nucleotide exchange factors of Rab5 and in integrin trafficking and focal adhesion turnover, which implicates in cell migration.
Collapse
Affiliation(s)
| | - Vasudevarao Penugurti
- Department of Biochemistry, School of Life Sciences, University of Hyderabad, Hyderabad, Telangana, India
| | - Suresh Bugide
- Department of Biochemistry, School of Life Sciences, University of Hyderabad, Hyderabad, Telangana, India
| | - Anju Dwivedi
- Department of Biochemistry, School of Life Sciences, University of Hyderabad, Hyderabad, Telangana, India
| | - Anita Kumari
- Department of Biochemistry, School of Life Sciences, University of Hyderabad, Hyderabad, Telangana, India
| | - P S Kesavan
- Department of Biological Sciences, Tata Institute of Fundamental Research (TIFR), Hyderabad, Telangana, India
| | - Sruchytha Kalali
- Department of Biochemistry, School of Life Sciences, University of Hyderabad, Hyderabad, Telangana, India
| | - Yasaswi Gayatri Mishra
- Department of Biochemistry, School of Life Sciences, University of Hyderabad, Hyderabad, Telangana, India
| | - Vakkalagadda A Ramesh
- Laboratory of Computational Biology, Centre for DNA Finger Printing and Diagnostics (CDFD), Hyderabad, Telangana, India; Laboratory of Computational Biology, Manipal Academy of Higher Education, Manipal, Karnataka, India
| | | | - Aprotim Mazumder
- Department of Biological Sciences, Tata Institute of Fundamental Research (TIFR), Hyderabad, Telangana, India
| | - Bramanandam Manavathi
- Department of Biochemistry, School of Life Sciences, University of Hyderabad, Hyderabad, Telangana, India.
| |
Collapse
|
2
|
Jiang Q, Zhang D, Liu J, Liang C, Yang R, Zhang C, Wu J, Lin J, Ye T, Ding L, Li J, Gao S, Li B, Ye Q. HPIP is an essential scaffolding protein running through the EGFR-RAS-ERK pathway and drives tumorigenesis. SCIENCE ADVANCES 2023; 9:eade1155. [PMID: 37294756 PMCID: PMC10256163 DOI: 10.1126/sciadv.ade1155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/25/2022] [Accepted: 05/04/2023] [Indexed: 06/11/2023]
Abstract
The EGFR-RAS-ERK pathway plays a key role in cancer development and progression. However, the integral assembly of EGFR-RAS-ERK signaling complexes from the upstream component EGFR to the downstream component ERK is largely unknown. Here, we show that hematopoietic PBX-interacting protein (HPIP) interacts with all classical components of the EGFR-RAS-ERK pathway and forms at least two complexes with overlapping components. Experiments of HPIP knockout or knockdown and chemical inhibition of HPIP expression showed that HPIP is required for EGFR-RAS-ERK signaling complex formation, EGFR-RAS-ERK signaling activation, and EGFR-RAS-ERK signaling-mediated promotion of aerobic glycolysis as well as cancer cell growth in vitro and in vivo. HPIP expression is correlated with EGFR-RAS-ERK signaling activation and predicts worse clinical outcomes in patients with lung cancer. These results provide insights into EGFR-RAS-ERK signaling complex formation and EGFR-RAS-ERK signaling regulation and suggest that HPIP may be a promising therapeutic target for cancer with dysregulated EGFR-RAS-ERK signaling.
Collapse
Affiliation(s)
- Qiwei Jiang
- Department of Cell Engineering, Beijing Institute of Biotechnology, Bejing 100850, China
- Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun 130122, China
| | - Deyu Zhang
- Department of Cell Engineering, Beijing Institute of Biotechnology, Bejing 100850, China
| | - Juan Liu
- Department of Cell Engineering, Beijing Institute of Biotechnology, Bejing 100850, China
- Department of Hematology, PLA Rocket Force Characteristic Medical Center, Beijing 100088, China
| | - Chaoyang Liang
- Department of Cell Engineering, Beijing Institute of Biotechnology, Bejing 100850, China
- Department of Thoracic Surgery, The First Medical Center, Chinese PLA General Hospital, Beijing 100853, China
| | - Ronghui Yang
- Beijing Institute of Hepatology, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China
| | - Cheng Zhang
- Outpatient Department, Jingnan Medical Area, Chinese PLA General Hospital, Beijing 100850, China
| | - Jun Wu
- Department of Microorganism Engineering, Beijing Institute of Biotechnology, Beijing 100071, China
| | - Jing Lin
- Department of Cell Engineering, Beijing Institute of Biotechnology, Bejing 100850, China
- Department of Clinical Laboratory, The Fourth Medical Center, Chinese PLA General Hospital, Beijing 100048, China
| | - Tianxing Ye
- Department of Cell Engineering, Beijing Institute of Biotechnology, Bejing 100850, China
| | - Lihua Ding
- Department of Cell Engineering, Beijing Institute of Biotechnology, Bejing 100850, China
| | - Jianbin Li
- Department of Cell Engineering, Beijing Institute of Biotechnology, Bejing 100850, China
| | - Shan Gao
- Zhongda Hospital, School of Life Sciences and Technology, Advanced Institute for Life and Health, Southeast University, Nanjing 210096, China
| | - Binghui Li
- Beijing Institute of Hepatology, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China
| | - Qinong Ye
- Department of Cell Engineering, Beijing Institute of Biotechnology, Bejing 100850, China
| |
Collapse
|
3
|
Bakr S, Brennan K, Mukherjee P, Argemi J, Hernaez M, Gevaert O. Identifying key multifunctional components shared by critical cancer and normal liver pathways via SparseGMM. CELL REPORTS METHODS 2023; 3:100392. [PMID: 36814838 PMCID: PMC9939431 DOI: 10.1016/j.crmeth.2022.100392] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/25/2022] [Revised: 09/16/2022] [Accepted: 12/21/2022] [Indexed: 01/19/2023]
Abstract
Despite the abundance of multimodal data, suitable statistical models that can improve our understanding of diseases with genetic underpinnings are challenging to develop. Here, we present SparseGMM, a statistical approach for gene regulatory network discovery. SparseGMM uses latent variable modeling with sparsity constraints to learn Gaussian mixtures from multiomic data. By combining coexpression patterns with a Bayesian framework, SparseGMM quantitatively measures confidence in regulators and uncertainty in target gene assignment by computing gene entropy. We apply SparseGMM to liver cancer and normal liver tissue data and evaluate discovered gene modules in an independent single-cell RNA sequencing (scRNA-seq) dataset. SparseGMM identifies PROCR as a regulator of angiogenesis and PDCD1LG2 and HNF4A as regulators of immune response and blood coagulation in cancer. Furthermore, we show that more genes have significantly higher entropy in cancer compared with normal liver. Among high-entropy genes are key multifunctional components shared by critical pathways, including p53 and estrogen signaling.
Collapse
Affiliation(s)
- Shaimaa Bakr
- Department of Electrical Engineering, Stanford University, Stanford, CA 94305, USA
- Stanford Center for Biomedical Informatics Research, Department of Medicine and Biomedical Data Science, Stanford University, Stanford, CA 94305, USA
- Department of Radiology, Stanford University, Stanford, CA 94305, USA
| | - Kevin Brennan
- Stanford Center for Biomedical Informatics Research, Department of Medicine and Biomedical Data Science, Stanford University, Stanford, CA 94305, USA
| | - Pritam Mukherjee
- Stanford Center for Biomedical Informatics Research, Department of Medicine and Biomedical Data Science, Stanford University, Stanford, CA 94305, USA
| | - Josepmaria Argemi
- Liver Unit, Clinica Universidad de Navarra, Hepatology Program, Center for Applied Medical Research, 31008 Pamplona, Navarra, Spain
| | - Mikel Hernaez
- Center for Applied Medical Research, University of Navarra, 31009 Pamplona, Navarra, Spain
| | - Olivier Gevaert
- Stanford Center for Biomedical Informatics Research, Department of Medicine and Biomedical Data Science, Stanford University, Stanford, CA 94305, USA
| |
Collapse
|
4
|
Marvalim C, Datta A, Lee SC. Role of p53 in breast cancer progression: An insight into p53 targeted therapy. Theranostics 2023; 13:1421-1442. [PMID: 36923534 PMCID: PMC10008729 DOI: 10.7150/thno.81847] [Citation(s) in RCA: 12] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2022] [Accepted: 01/26/2023] [Indexed: 03/14/2023] Open
Abstract
The transcription factor p53 is an important regulator of a multitude of cellular processes. In the presence of genotoxic stress, p53 is activated to facilitate DNA repair, cell cycle arrest, and apoptosis. In breast cancer, the tumor suppressive activities of p53 are frequently inactivated by either the overexpression of its negative regulator MDM2, or mutation which is present in 30-35% of all breast cancer cases. Notably, the frequency of p53 mutation is highly subtype dependent in breast cancers, with majority of hormone receptor-positive or luminal subtypes retaining the wild-type p53 status while hormone receptor-negative patients predominantly carry p53 mutations with gain-of-function oncogenic activities that contribute to poorer prognosis. Thus, a two-pronged strategy of targeting wild-type and mutant p53 in different subtypes of breast cancer can have clinical relevance. The development of p53-based therapies has rapidly progressed in recent years, and include unique small molecule chemical inhibitors, stapled peptides, PROTACs, as well as several genetic-based approaches using vectors and engineered antibodies. In this review, we highlight the therapeutic strategies that are in pre-clinical and clinical development to overcome p53 inactivation in both wild-type and mutant p53-bearing breast tumors, and discuss their efficacies and limitations in pre-clinical and clinical settings.
Collapse
Affiliation(s)
- Charlie Marvalim
- Cancer Science Institute of Singapore, Singapore 117599, Singapore
- ✉ Corresponding authors: C.M. E-mail: ; L.S.C. E-mail: ; Tel: (65) 6516 7282
| | - Arpita Datta
- Cancer Science Institute of Singapore, Singapore 117599, Singapore
| | - Soo Chin Lee
- Cancer Science Institute of Singapore, Singapore 117599, Singapore
- Department of Haematology-Oncology, National University Cancer Institute, Singapore, National University Health System, Singapore 119228, Singapore
- ✉ Corresponding authors: C.M. E-mail: ; L.S.C. E-mail: ; Tel: (65) 6516 7282
| |
Collapse
|
5
|
Tang SC, Lion Q, Peulen O, Chariot P, Lavergne A, Mayer A, Fuster PA, Close P, Klein S, Florin A, Büttner R, Nemazanyy I, Shostak K, Chariot A. The E3 ligase COP1 promotes ERα signaling and suppresses EMT in breast cancer. Oncogene 2021; 41:173-190. [PMID: 34716429 DOI: 10.1038/s41388-021-02038-3] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2021] [Revised: 09/14/2021] [Accepted: 09/23/2021] [Indexed: 01/22/2023]
Abstract
ERα signaling drives proliferation, survival and cancer initiation in the mammary gland. Therefore, it is critical to elucidate mechanisms by which ERα expression is regulated. We show that the tumor suppressor E3 ligase COP1 promotes the degradative polyubiquitination of the microtubule-associated protein HPIP. As such, COP1 negatively regulates estrogen-dependent AKT activation in breast cancer cells. However, COP1 also induces ERα expression and ERα-dependent gene transcription, at least through c-Jun degradation. COP1 and ERα levels are positively correlated in clinical cases of breast cancer. COP1 also supports the metabolic reprogramming by estrogens, including glycolysis. On the other hand, COP1 suppresses EMT in breast cancer cells. COP1 deficiency also contributes to Tamoxifen resistance, at least through protective autophagy. Therefore, COP1 acts as an oncogenic E3 ligase by promoting ERα signaling but also acts as a tumor suppressor candidate by preventing EMT, which reflects a dual role of COP1 in breast cancer.
Collapse
Affiliation(s)
- Seng Chuan Tang
- Interdisciplinary Cluster for Applied Genoproteomics, University of Liege, CHU, Sart-Tilman, Liège, Belgium.,Laboratory of Medical Chemistry, GIGA Stem Cells, University of Liege, CHU, Sart-Tilman, Liège, Belgium
| | - Quentin Lion
- Interdisciplinary Cluster for Applied Genoproteomics, University of Liege, CHU, Sart-Tilman, Liège, Belgium.,Laboratory of Medical Chemistry, GIGA Stem Cells, University of Liege, CHU, Sart-Tilman, Liège, Belgium
| | - Olivier Peulen
- Interdisciplinary Cluster for Applied Genoproteomics, University of Liege, CHU, Sart-Tilman, Liège, Belgium.,Metastasis Research Laboratory, GIGA Cancer, University of Liege, CHU, Sart-Tilman, Liège, Belgium
| | - Philippe Chariot
- Interdisciplinary Cluster for Applied Genoproteomics, University of Liege, CHU, Sart-Tilman, Liège, Belgium.,Laboratory of Medical Chemistry, GIGA Stem Cells, University of Liege, CHU, Sart-Tilman, Liège, Belgium
| | - Arnaud Lavergne
- Interdisciplinary Cluster for Applied Genoproteomics, University of Liege, CHU, Sart-Tilman, Liège, Belgium.,GIGA Genomics Platform, University of Liege, CHU, Sart-Tilman, Liège, Belgium
| | - Alice Mayer
- Interdisciplinary Cluster for Applied Genoproteomics, University of Liege, CHU, Sart-Tilman, Liège, Belgium.,GIGA Genomics Platform, University of Liege, CHU, Sart-Tilman, Liège, Belgium
| | - Paula Allepuz Fuster
- Interdisciplinary Cluster for Applied Genoproteomics, University of Liege, CHU, Sart-Tilman, Liège, Belgium.,Laboratory of Medical Chemistry, GIGA Stem Cells, University of Liege, CHU, Sart-Tilman, Liège, Belgium
| | - Pierre Close
- Interdisciplinary Cluster for Applied Genoproteomics, University of Liege, CHU, Sart-Tilman, Liège, Belgium.,Laboratory of Cancer Signaling, GIGA Stem Cells, University of Liege, CHU, Sart-Tilman, 4000, Liège, Belgium.,Walloon Excellence in Life Sciences and Biotechnology (WELBIO), Wavres, Belgium
| | - Sebastian Klein
- Institute for Pathology-University Hospital of Cologne, Cologne, Germany
| | - Alexandra Florin
- Institute for Pathology-University Hospital of Cologne, Cologne, Germany
| | - Reinhard Büttner
- Institute for Pathology-University Hospital of Cologne, Cologne, Germany
| | - Ivan Nemazanyy
- Platform for Metabolic Analyses, Structure Fédérative de Recherche Necker, INSERM US24/CNRS UMS 3633, Paris, France
| | - Kateryna Shostak
- Interdisciplinary Cluster for Applied Genoproteomics, University of Liege, CHU, Sart-Tilman, Liège, Belgium.,Laboratory of Medical Chemistry, GIGA Stem Cells, University of Liege, CHU, Sart-Tilman, Liège, Belgium
| | - Alain Chariot
- Interdisciplinary Cluster for Applied Genoproteomics, University of Liege, CHU, Sart-Tilman, Liège, Belgium. .,Laboratory of Medical Chemistry, GIGA Stem Cells, University of Liege, CHU, Sart-Tilman, Liège, Belgium. .,Walloon Excellence in Life Sciences and Biotechnology (WELBIO), Wavres, Belgium.
| |
Collapse
|
6
|
A novel chemical inhibitor suppresses breast cancer cell growth and metastasis through inhibiting HPIP oncoprotein. Cell Death Discov 2021; 7:198. [PMID: 34326318 PMCID: PMC8322322 DOI: 10.1038/s41420-021-00580-3] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2021] [Revised: 06/07/2021] [Accepted: 07/03/2021] [Indexed: 11/09/2022] Open
Abstract
Increasing evidence suggests the pivotal role of hematopoietic pre-B-cell leukemia transcription factor (PBX)-interacting protein (HPIP/PBXIP1) in cancer development and progression, indicating that HPIP inhibition may be a promising target for cancer therapy. Here, we screened compounds inhibiting breast cancer cell proliferation with HPIP fused with green fluorescent protein as a reporter. A novel agent named TXX-1-10 derived from rimonabant, an antagonist of cannabinoid receptor 1 with anticancer effects, has been discovered to reduce HPIP expression and has greater inhibitory effects on breast cancer cell growth and metastasis in vitro and in vivo than rimonabant. TXX-1-10 regulates HPIP downstream targets, including several important kinases involved in cancer development and progression (e.g., AKT, ERK1/2, and FAK) as well as cell cycle-, apoptosis-, migration-, and epithelial-to-mesenchymal transition (EMT)-related genes. Consistent with the results of anticancer effects, genome-wide RNA sequencing indicated that TXX-1-10 has more significant effects on regulation of the expression of genes related to DNA replication, cell cycle, apoptosis, cell adhesion, cell migration, and invasion than rimonabant. In addition, TXX-1-10 significantly regulated genes associated with the cell growth and extracellular matrix organization, many of which were shown to be regulated by HPIP. Moreover, compared with rimonabant, TXX-1-10 greatly reduces blood-brain barrier penetrability to avoid adverse central depressive effects. These findings suggest that HPIP inhibition may be a useful strategy for cancer treatment and TXX-1-10 is a promising candidate drug for cancer therapy.
Collapse
|
7
|
Penugurti V, Khumukcham SS, Padala C, Dwivedi A, Kamireddy KR, Mukta S, Bhopal T, Manavathi B. HPIP protooncogene differentially regulates metabolic adaptation and cell fate in breast cancer cells under glucose stress via AMPK and RNF2 dependent pathways. Cancer Lett 2021; 518:243-255. [PMID: 34302919 DOI: 10.1016/j.canlet.2021.07.027] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2021] [Revised: 06/27/2021] [Accepted: 07/19/2021] [Indexed: 12/13/2022]
Abstract
While cancer cells rewire metabolic pathways to sustain growth and survival under metabolic stress in solid tumors, the molecular mechanisms underlying these processes remain largely unknown. In this study, cancer cells switched from survival to death during the early to late phases of metabolic stress by employing a novel signaling switch from AMP activated protein kinase (AMPK)-Forkhead box O3 (FOXO3a)-hematopoietic PBX1-interacting protein (HPIP) to the ring finger protein 2 (RNF2)-HPIP-ubiquitin (Ub) pathway. Acute metabolic stress induced proto-oncogene HPIP expression in an AMPK-FOXO3a-dependent manner in breast cancer (BC) cells. HPIP depletion reduced cell survival and tumor formation in mouse xenografts, which was accompanied by diminished intracellular ATP levels and increased apoptosis in BC cells in response to metabolic (glucose) stress. Glutamine flux (13C-labeled) analysis further suggested that HPIP rewired glutamine metabolism by controlling the expression of the solute carrier family 1 member 5 (SLC1A5) and glutaminase (GLS) genes by acting as a coactivator of MYC to ensure cell survival upon glucose deprivation. However, in response to chronic glucose stress, HPIP was ubiquitinated by the E3-Ub ligase, RNF2, and was concomitantly degraded by the proteasome-mediated pathway, ensuring apoptosis. In support of these data, clinical analyses further indicated that elevated levels of HPIP correlated with AMPK activation in BC. Taken together, these data suggest that HPIP is a signal coordinator during metabolic stress and thus serves as a potential therapeutic target in BC.
Collapse
Affiliation(s)
- Vasudevarao Penugurti
- Molecular and Cellular Oncology Laboratory, Department of Biochemistry, School of Life Sciences, University of Hyderabad, Hyderabad, 500046, Telangana, India
| | - Saratchandra Singh Khumukcham
- Molecular and Cellular Oncology Laboratory, Department of Biochemistry, School of Life Sciences, University of Hyderabad, Hyderabad, 500046, Telangana, India
| | - Chiranjeevi Padala
- Molecular and Cellular Oncology Laboratory, Department of Biochemistry, School of Life Sciences, University of Hyderabad, Hyderabad, 500046, Telangana, India
| | - Anju Dwivedi
- Molecular and Cellular Oncology Laboratory, Department of Biochemistry, School of Life Sciences, University of Hyderabad, Hyderabad, 500046, Telangana, India
| | - Karthik Reddy Kamireddy
- Molecular and Cellular Biology Laboratory, Baylor College of Medicine, Houston, TX, United States
| | - Srinivasulu Mukta
- MNJ Institute of Oncology and Regional Cancer Center, Hyderabad, 500004, Telangana, India
| | - Triveni Bhopal
- MNJ Institute of Oncology and Regional Cancer Center, Hyderabad, 500004, Telangana, India
| | - Bramanandam Manavathi
- Molecular and Cellular Oncology Laboratory, Department of Biochemistry, School of Life Sciences, University of Hyderabad, Hyderabad, 500046, Telangana, India.
| |
Collapse
|
8
|
Khumukcham SS, Manavathi B. Two decades of a protooncogene HPIP/PBXIP1: Uncovering the tale from germ cell to cancer. Biochim Biophys Acta Rev Cancer 2021; 1876:188576. [PMID: 34090932 DOI: 10.1016/j.bbcan.2021.188576] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2021] [Revised: 05/25/2021] [Accepted: 05/28/2021] [Indexed: 01/17/2023]
Abstract
Hematopoietic PBX interacting protein (HPIP or pre-B-cell leukemia transcription factor interacting protein (PBXIP1) was discovered two decades ago as a corepressor of pre-B-cell leukemia homeobox (PBX) 1 with a vital functional role in hematopoiesis. Later it emerged as a potential biomarker of poor prognosis and tumorigenesis for more than a dozen different cancers. It regulates aggressive cancer phenotypes, cell proliferation, metastasis, EMT, etc. The anomaly in the regulation of HPIP is linked with physiological disorders like renal fibrosis, chronic kidney disease and osteoarthritis. Scientists have unraveled more than twenty interacting proteins of HPIP and its functional role in various physiological and cellular processes that involves normal neuronal development, embryogenesis, endometrium decidualization, and germ cell proliferation. Over the past 20 years, we have witnessed the emerging role of HPIP and its association with a myriad of cellular activities ranging from germ cell proliferation to cancer aggressiveness, modulating multitude of signaling cascades like TGF-β1, PI3K/AKT, Wnt, mTOR, and Sonic hedgehog signaling pathways. This review will give the current understanding of HPIP, in terms of its diverse functions, theoretical ideas, and further explore cellular links and promising areas that need to be investigated. We also provide a comprehensive overview of the transcript variants of HPIP and distinct sets of transcription factors regulating their expression, which may help to understand the role of HPIP in various cellular or physiological conditions.
Collapse
Affiliation(s)
- Saratchandra Singh Khumukcham
- Molecular and Cellular Oncology Laboratory, Department of Biochemistry, School of Life Sciences, University of Hyderabad, Hyderabad, Telangana, India
| | - Bramanandam Manavathi
- Molecular and Cellular Oncology Laboratory, Department of Biochemistry, School of Life Sciences, University of Hyderabad, Hyderabad, Telangana, India.
| |
Collapse
|
9
|
Zhao C, Zhao W. TANK-binding kinase 1 as a novel therapeutic target for viral diseases. Expert Opin Ther Targets 2019; 23:437-446. [DOI: 10.1080/14728222.2019.1601702] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Affiliation(s)
- Chunyuan Zhao
- Department of Immunology, School of Basic Medical Science, Shandong University, Jinan, China
- State Key Laboratory of Microbial Technology, Shandong University, Jinan, China
- Department of Cell Biology, School of Basic Medical Science, Shandong University, Jinan, China
| | - Wei Zhao
- Department of Immunology, School of Basic Medical Science, Shandong University, Jinan, China
- State Key Laboratory of Microbial Technology, Shandong University, Jinan, China
- Department of Cell Biology, School of Basic Medical Science, Shandong University, Jinan, China
| |
Collapse
|
10
|
Wang Y, Li D, Liu Y, tian S, Chen X. Expression and clinicopathological significance of hematopoietic pre-B cell leukemia transcription factor-interacting protein in cervical carcinoma. Pathol Res Pract 2018; 214:1340-1344. [DOI: 10.1016/j.prp.2017.07.031] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/08/2017] [Revised: 07/11/2017] [Accepted: 07/28/2017] [Indexed: 10/19/2022]
|
11
|
Haupt S, Vijayakumaran R, Miranda PJ, Burgess A, Lim E, Haupt Y. The role of MDM2 and MDM4 in breast cancer development and prevention. J Mol Cell Biol 2017; 9:53-61. [PMID: 28096293 PMCID: PMC5439375 DOI: 10.1093/jmcb/mjx007] [Citation(s) in RCA: 41] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2016] [Accepted: 01/16/2017] [Indexed: 01/13/2023] Open
Abstract
The major cause of death from breast cancer is not the primary tumour, but relapsing, drug-resistant, metastatic disease. Identifying factors that contribute to aggressive cancer offers important leads for therapy. Inherent defence against carcinogens depends on the individual molecular make-up of each person. Important molecular determinants of these responses are under the control of the mouse double minute (MDM) family: comprised of the proteins MDM2 and MDM4. In normal, healthy adult cells, the MDM family functions to critically regulate measured, cellular responses to stress and subsequent recovery. Proper function of the MDM family is vital for normal breast development, but also for preserving genomic fidelity. The MDM family members are best characterized for their negative regulation of the major tumour suppressor p53 to modulate stress responses. Their impact on other cellular regulators is emerging. Inappropriately elevated protein levels of the MDM family are highly associated with an increased risk of cancer incidence. Exploration of the MDM family members as cancer therapeutic targets is relevant for designing tailored anti-cancer treatments, but successful approaches must strategically consider the impact on both the target cancer and adjacent healthy cells and tissues. This review focuses on recent findings pertaining to the role of the MDM family in normal and malignant breast cells.
Collapse
Affiliation(s)
- Sue Haupt
- Tumour Suppression Laboratory, Peter MacCallum Cancer Centre, Melbourne 3000, Australia
| | - Reshma Vijayakumaran
- Tumour Suppression Laboratory, Peter MacCallum Cancer Centre, Melbourne 3000, Australia.,Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne 3000, Australia
| | - Panimaya Jeffreena Miranda
- Tumour Suppression Laboratory, Peter MacCallum Cancer Centre, Melbourne 3000, Australia.,Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne 3000, Australia
| | - Andrew Burgess
- The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, New South Wales 2010, Australia.,St. Vincent's Clinical School, Faculty of Medicine, University of New South Wales, Sydney, New South Wales 2010, Australia
| | - Elgene Lim
- The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, New South Wales 2010, Australia.,St. Vincent's Clinical School, Faculty of Medicine, University of New South Wales, Sydney, New South Wales 2010, Australia
| | - Ygal Haupt
- Tumour Suppression Laboratory, Peter MacCallum Cancer Centre, Melbourne 3000, Australia.,Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne 3000, Australia.,Department of Pathology, The University of Melbourne, Parkville, Victoria 3010, Australia.,Department of Biochemistry and Molecular Biology, Monash University, Clayton, Australia
| |
Collapse
|
12
|
Cao S, Sun J, Lin S, Zhao L, Wu D, Liang T, Sheng W. HPIP: a predictor of lymph node metastasis and poor survival in cervical cancer. Onco Targets Ther 2017; 10:4205-4211. [PMID: 28894377 PMCID: PMC5584897 DOI: 10.2147/ott.s141248] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Background The aim of this study was to explore the relationships of HPIP expression status with the clinicopathological variables and survival outcomes of patients with cervical cancer (CC). Methods We compared the HPIP expression of 119 samples from CC tissues, 20 from cervical intraepithelial tissues, and 20 from normal cervical tissues by using immunohistochemical staining. Results It was observed that the ratio of elevated HPIP expression was higher in CC tissues than in cervical intraepithelial neoplasia (P=0.017) and normal cervical tissues (P=0.001). In addition, there was an association between HPIP and clinicopathological factors, such as histological grade (P<0.001), stromal infiltration (P=0.015), lymph node metastasis (P<0.001), lymphovascular space invasion (LVSI; P=0.026), and recurrence (P=0.029). Furthermore, multivariate Cox regression analysis revealed that high HPIP expression (P=0.027 and P=0.042) as well as the International Federation of Gynaecology and Obstetrics stage (P=0.003 and P=0.009), lymph node metastasis (P=0.031 and P=0.017), and LVSI (P=0.024 and P=0.046) were independent prognostic factors. In addition, we demonstrated that high HPIP expression (P=0.003) and LVSI (P<0.001) were independently related to lymph node metastasis. Conclusion Elevated HPIP expression may contribute to the progression and metastasis of CC and may also serve as a new biomarker to predict the prognosis of CC.
Collapse
Affiliation(s)
- Shan Cao
- Department of Gynecology and Obstetrics, The First Affiliated Hospital of Harbin Medical University, Harbin, People's Republic of China
| | - Jingxia Sun
- Department of Gynecology and Obstetrics, The First Affiliated Hospital of Harbin Medical University, Harbin, People's Republic of China
| | - Shuai Lin
- Department of Gynecology and Obstetrics, The First Affiliated Hospital of Harbin Medical University, Harbin, People's Republic of China
| | - Lu Zhao
- Department of Gynecology and Obstetrics, The First Affiliated Hospital of Harbin Medical University, Harbin, People's Republic of China
| | - Di Wu
- Department of Gynecology and Obstetrics, The First Affiliated Hospital of Harbin Medical University, Harbin, People's Republic of China
| | - Tian Liang
- Department of Gynecology and Obstetrics, The First Affiliated Hospital of Harbin Medical University, Harbin, People's Republic of China
| | - Wenji Sheng
- Department of Gynecology and Obstetrics, The First Affiliated Hospital of Harbin Medical University, Harbin, People's Republic of China
| |
Collapse
|
13
|
Wang Y, Li M, Meng F, Lou G. HPIP expression predicts chemoresistance and poor clinical outcomes in patients with epithelial ovarian cancer. Hum Pathol 2017; 60:114-120. [DOI: 10.1016/j.humpath.2016.10.015] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/30/2016] [Revised: 10/05/2016] [Accepted: 10/14/2016] [Indexed: 01/05/2023]
|
14
|
Bugide S, Gonugunta VK, Penugurti V, Malisetty VL, Vadlamudi RK, Manavathi B. HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation. Cell Oncol (Dordr) 2016; 40:133-144. [PMID: 28039608 DOI: 10.1007/s13402-016-0308-2] [Citation(s) in RCA: 48] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/01/2016] [Indexed: 12/30/2022] Open
Abstract
PURPOSE Hematopoietic PBX interacting protein (HPIP), a scaffold protein, is known to regulate the proliferation, migration and invasion in different cancer cell types. The aim of this study was to assess the role of HPIP in ovarian cancer cell migration, invasion and epithelial-mesenchymal transition (EMT), and to unravel the mechanism by which it regulates these processes. METHODS HPIP expression was assessed by immunohistochemistry of tissue microarrays containing primary ovarian tumor samples of different grades. OAW42, an ovarian carcinoma-derived cell line exhibiting a high HPIP expression, was used to study the role of HPIP in cell migration, invasion and EMT. HPIP knockdown in these cells was achieved using a small hairpin RNA (shRNA) approach. Cell migration and invasion were assessed using scratch wound and transwell invasion assays, respectively. The extent of EMT was assessed by determining the expression levels of Snail, Vimentin and E-cadherin using Western blotting. The effect of HPIP expression on AKT and MAPK activation was also investigated by Western blotting. Cell viabilities in response to cisplatin treatment were assessed using a MTT assay, whereas apoptosis was assessed by determining caspase-3 and PARP cleavage in ovarian carcinoma-derived SKOV3 cells. RESULTS We found that HPIP is highly expressed in high-grade primary ovarian tumors. In addition, we found that HPIP promotes the migration, invasion and EMT in OAW42 cells and induces EMT in these cells via activation of the PI3K/AKT pathway. The latter was found to lead to stabilization of the Snail protein and to repression of E-cadherin expression through inactivation of GSK-3β. We also found that HPIP expression confers cisplatin resistance to SKOV3 cells after prolonged exposure and that its subsequent knockdown decreases the viability of these cells and increases caspase-3 activation and PARP proteolysis in these cells following cisplatin treatment. CONCLUSIONS From these results we conclude that HPIP expression is associated with high-grade ovarian tumors and may promote their migration, invasion and EMT, a process that is associated with metastasis. In addition, we conclude that HPIP may serve as a potential therapeutic target for cisplatin resistant ovarian tumors.
Collapse
Affiliation(s)
- Suresh Bugide
- Department of Biochemistry, School of Life Sciences, University of Hyderabad, Hyderabad, 500046, India
| | | | - Vasudevarao Penugurti
- Department of Biochemistry, School of Life Sciences, University of Hyderabad, Hyderabad, 500046, India
| | | | - Ratna K Vadlamudi
- Department of Obstetrics and Gynecology, UT Health Science Center, San Antonio, USA
| | - Bramanandam Manavathi
- Department of Biochemistry, School of Life Sciences, University of Hyderabad, Hyderabad, 500046, India.
| |
Collapse
|
15
|
Wang Y, Meng F, Liu Y, Chen X. Expression of HPIP in epithelial ovarian carcinoma: a clinicopathological study. Onco Targets Ther 2016; 10:95-100. [PMID: 28053543 PMCID: PMC5189975 DOI: 10.2147/ott.s114884] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023] Open
Abstract
Objectives Hematopoietic pre-B-cell leukemia transcription factor (PBX)-interacting protein (HPIP) plays an important role in cancer invasion and metastasis. The aim of this study is to investigate the expression of HPIP in epithelial ovarian cancer (EOC). Patients and methods Immunohistochemical method was performed using 42 normal ovarian specimens and 145 specimens with EOC. The correlations of HPIP expression with the clinicopathological factors and prognosis of EOC patients were evaluated. Statistical analyses were performed using the chi-square test, multivariate Cox proportional hazard, and Kaplan–Meier method. Results HPIP expression in EOC was higher than that in normal tissues (P<0.001). HPIP expression was significantly associated with histological grade, International Federation of Gynecology and Obstetrics stage, and lymphatic metastasis of EOC (P<0.05). Patients with high HPIP expression had poorer overall survival and disease-free survival (P<0.001) compared with patients with low HPIP expression. Multivariate Cox analysis demonstrated that HPIP was an independent factor for overall survival and disease-free survival (P<0.05). Conclusion HPIP may be a valuable biomarker for predicting the prognosis of EOC patients and may serve as a potential target for cancer therapy.
Collapse
Affiliation(s)
- Yuping Wang
- Department of Gynecology, The Affiliated Tumor Hospital, Harbin Medical University, Harbin, People's Republic of China
| | - Fanling Meng
- Department of Gynecology, The Affiliated Tumor Hospital, Harbin Medical University, Harbin, People's Republic of China
| | - Yunduo Liu
- Department of Gynecology, The Affiliated Tumor Hospital, Harbin Medical University, Harbin, People's Republic of China
| | - Xiuwei Chen
- Department of Gynecology, The Affiliated Tumor Hospital, Harbin Medical University, Harbin, People's Republic of China
| |
Collapse
|
16
|
Göktuna SI, Shostak K, Chau TL, Heukamp LC, Hennuy B, Duong HQ, Ladang A, Close P, Klevernic I, Olivier F, Florin A, Ehx G, Baron F, Vandereyken M, Rahmouni S, Vereecke L, van Loo G, Büttner R, Greten FR, Chariot A. The Prosurvival IKK-Related Kinase IKKε Integrates LPS and IL17A Signaling Cascades to Promote Wnt-Dependent Tumor Development in the Intestine. Cancer Res 2016; 76:2587-99. [PMID: 26980769 DOI: 10.1158/0008-5472.can-15-1473] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2015] [Accepted: 02/13/2016] [Indexed: 11/16/2022]
Abstract
Constitutive Wnt signaling promotes intestinal cell proliferation, but signals from the tumor microenvironment are also required to support cancer development. The role that signaling proteins play to establish a tumor microenvironment has not been extensively studied. Therefore, we assessed the role of the proinflammatory Ikk-related kinase Ikkε in Wnt-driven tumor development. We found that Ikkε was activated in intestinal tumors forming upon loss of the tumor suppressor Apc Genetic ablation of Ikkε in β-catenin-driven models of intestinal cancer reduced tumor incidence and consequently extended survival. Mechanistically, we attributed the tumor-promoting effects of Ikkε to limited TNF-dependent apoptosis in transformed intestinal epithelial cells. In addition, Ikkε was also required for lipopolysaccharide (LPS) and IL17A-induced activation of Akt, Mek1/2, Erk1/2, and Msk1. Accordingly, genes encoding pro-inflammatory cytokines, chemokines, and anti-microbial peptides were downregulated in Ikkε-deficient tissues, subsequently affecting the recruitment of tumor-associated macrophages and IL17A synthesis. Further studies revealed that IL17A synergized with commensal bacteria to trigger Ikkε phosphorylation in transformed intestinal epithelial cells, establishing a positive feedback loop to support tumor development. Therefore, TNF, LPS, and IL17A-dependent signaling pathways converge on Ikkε to promote cell survival and to establish an inflammatory tumor microenvironment in the intestine upon constitutive Wnt activation. Cancer Res; 76(9); 2587-99. ©2016 AACR.
Collapse
Affiliation(s)
- Serkan Ismail Göktuna
- Interdisciplinary Cluster for Applied Genoproteomics (GIGA), University of Liege, Liège, Belgium. Laboratory of Medical Chemistry, GIGA Molecular Biology of Diseases, University of Liege, Liège, Belgium. Department of Molecular Biology and Genetics, Bilkent University, Bilkent, Ankara, Turkey
| | - Kateryna Shostak
- Interdisciplinary Cluster for Applied Genoproteomics (GIGA), University of Liege, Liège, Belgium. Laboratory of Medical Chemistry, GIGA Molecular Biology of Diseases, University of Liege, Liège, Belgium
| | - Tieu-Lan Chau
- Interdisciplinary Cluster for Applied Genoproteomics (GIGA), University of Liege, Liège, Belgium. Laboratory of Medical Chemistry, GIGA Molecular Biology of Diseases, University of Liege, Liège, Belgium
| | - Lukas C Heukamp
- Institute for Pathology-University Hospital Cologne, Germany
| | - Benoit Hennuy
- Interdisciplinary Cluster for Applied Genoproteomics (GIGA), University of Liege, Liège, Belgium. GIGA Transcriptomic Facility, University of Liege, CHU, Sart-Tilman, Liège, Belgium
| | - Hong-Quan Duong
- Interdisciplinary Cluster for Applied Genoproteomics (GIGA), University of Liege, Liège, Belgium. Laboratory of Medical Chemistry, GIGA Molecular Biology of Diseases, University of Liege, Liège, Belgium
| | - Aurélie Ladang
- Interdisciplinary Cluster for Applied Genoproteomics (GIGA), University of Liege, Liège, Belgium. Laboratory of Medical Chemistry, GIGA Molecular Biology of Diseases, University of Liege, Liège, Belgium
| | - Pierre Close
- Interdisciplinary Cluster for Applied Genoproteomics (GIGA), University of Liege, Liège, Belgium. Laboratory of Cancer Signaling, GIGA Molecular Biology of Diseases, University of Liege, Liège, Belgium
| | - Iva Klevernic
- Interdisciplinary Cluster for Applied Genoproteomics (GIGA), University of Liege, Liège, Belgium. Laboratory of Medical Chemistry, GIGA Molecular Biology of Diseases, University of Liege, Liège, Belgium
| | - Fabrice Olivier
- Interdisciplinary Cluster for Applied Genoproteomics (GIGA), University of Liege, Liège, Belgium. Animal Facility, Liège, University of Liege, Belgium
| | | | - Grégory Ehx
- Interdisciplinary Cluster for Applied Genoproteomics (GIGA), University of Liege, Liège, Belgium. Unit of Hematology and Department of Medicine, Division of Hematology, GIGA-I, University of Liege, Liège, Belgium
| | - Frédéric Baron
- Interdisciplinary Cluster for Applied Genoproteomics (GIGA), University of Liege, Liège, Belgium. Unit of Hematology and Department of Medicine, Division of Hematology, GIGA-I, University of Liege, Liège, Belgium
| | - Maud Vandereyken
- Interdisciplinary Cluster for Applied Genoproteomics (GIGA), University of Liege, Liège, Belgium. Unit of Immunology and Infectious Diseases, GIGA Molecular Biology of Diseases, University of Liege, Liège, Belgium
| | - Souad Rahmouni
- Interdisciplinary Cluster for Applied Genoproteomics (GIGA), University of Liege, Liège, Belgium. Unit of Immunology and Infectious Diseases, GIGA Molecular Biology of Diseases, University of Liege, Liège, Belgium
| | - Lars Vereecke
- Inflammation Research Centre (IRC), VIB, Ghent, Belgium. Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium
| | - Geert van Loo
- Inflammation Research Centre (IRC), VIB, Ghent, Belgium. Department of Biomedical Molecular Biology, Ghent University, Ghent, Belgium
| | | | - Florian R Greten
- Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, 60596 Frankfurt am Main, Germany
| | - Alain Chariot
- Interdisciplinary Cluster for Applied Genoproteomics (GIGA), University of Liege, Liège, Belgium. Laboratory of Medical Chemistry, GIGA Molecular Biology of Diseases, University of Liege, Liège, Belgium. Walloon Excellence in Life Sciences and Biotechnology (WELBIO), University of Liege, Liège, Belgium.
| |
Collapse
|
17
|
Chau TL, Göktuna SI, Rammal A, Casanova T, Duong HQ, Gatot JS, Close P, Dejardin E, Desmecht D, Shostak K, Chariot A. A role for APPL1 in TLR3/4-dependent TBK1 and IKKε activation in macrophages. THE JOURNAL OF IMMUNOLOGY 2015; 194:3970-83. [PMID: 25780039 DOI: 10.4049/jimmunol.1401614] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/25/2014] [Accepted: 02/03/2015] [Indexed: 01/07/2023]
Abstract
Endosomes have important roles in intracellular signal transduction as a sorting platform. Signaling cascades from TLR engagement to IRF3-dependent gene transcription rely on endosomes, yet the proteins that specifically recruit IRF3-activating molecules to them are poorly defined. We show that adaptor protein containing a pleckstrin-homology domain, a phosphotyrosine-binding domain, and a leucine zipper motif (APPL)1, an early endosomal protein, is required for both TRIF- and retinoic acid-inducible gene 1-dependent signaling cascades to induce IRF3 activation. APPL1, but not early endosome Ag 1, deficiency impairs IRF3 target gene expression upon engagement of both TLR3 and TLR4 pathways, as well as in H1N1-infected macrophages. The IRF3-phosphorylating kinases TBK1 and IKKε are recruited to APPL1 endosomes in LPS-stimulated macrophages. Interestingly, APPL1 undergoes proteasome-mediated degradation through ERK1/2 to turn off signaling. APPL1 degradation is blocked when signaling through the endosome is inhibited by chloroquine or dynasore. Therefore, APPL1 endosomes are critical for IRF3-dependent gene expression in response to some viral and bacterial infections in macrophages. Those signaling pathways involve the signal-induced degradation of APPL1 to prevent aberrant IRF3-dependent gene expression linked to immune diseases.
Collapse
Affiliation(s)
- Tieu-Lan Chau
- Interdisciplinary Cluster of Applied Genoproteomics, GIGA-Research, Hospital University of Liege Sart-Tilman, University of Liege, 4000 Liege, Belgium; Laboratory of Medical Chemistry, Hospital University of Liege Sart-Tilman, University of Liege, 4000 Liege, Belgium; Unit of Signal Transduction, GIGA-Research, Hospital University of Liege Sart-Tilman, University of Liege, 4000 Liege, Belgium
| | - Serkan Ismail Göktuna
- Interdisciplinary Cluster of Applied Genoproteomics, GIGA-Research, Hospital University of Liege Sart-Tilman, University of Liege, 4000 Liege, Belgium; Laboratory of Medical Chemistry, Hospital University of Liege Sart-Tilman, University of Liege, 4000 Liege, Belgium; Unit of Signal Transduction, GIGA-Research, Hospital University of Liege Sart-Tilman, University of Liege, 4000 Liege, Belgium
| | - Ayman Rammal
- Interdisciplinary Cluster of Applied Genoproteomics, GIGA-Research, Hospital University of Liege Sart-Tilman, University of Liege, 4000 Liege, Belgium; Laboratory of Medical Chemistry, Hospital University of Liege Sart-Tilman, University of Liege, 4000 Liege, Belgium; Unit of Signal Transduction, GIGA-Research, Hospital University of Liege Sart-Tilman, University of Liege, 4000 Liege, Belgium
| | - Tomás Casanova
- Department of Veterinary Pathology, Fundamental and Applied Research for Animals and Health, University of Liege, 4000 Liege, Belgium
| | - Hong-Quan Duong
- Interdisciplinary Cluster of Applied Genoproteomics, GIGA-Research, Hospital University of Liege Sart-Tilman, University of Liege, 4000 Liege, Belgium; Laboratory of Medical Chemistry, Hospital University of Liege Sart-Tilman, University of Liege, 4000 Liege, Belgium; Unit of Signal Transduction, GIGA-Research, Hospital University of Liege Sart-Tilman, University of Liege, 4000 Liege, Belgium
| | - Jean-Stéphane Gatot
- Interdisciplinary Cluster of Applied Genoproteomics, GIGA-Research, Hospital University of Liege Sart-Tilman, University of Liege, 4000 Liege, Belgium; Laboratory of Medical Chemistry, Hospital University of Liege Sart-Tilman, University of Liege, 4000 Liege, Belgium; Unit of Signal Transduction, GIGA-Research, Hospital University of Liege Sart-Tilman, University of Liege, 4000 Liege, Belgium
| | - Pierre Close
- Interdisciplinary Cluster of Applied Genoproteomics, GIGA-Research, Hospital University of Liege Sart-Tilman, University of Liege, 4000 Liege, Belgium; Laboratory of Medical Chemistry, Hospital University of Liege Sart-Tilman, University of Liege, 4000 Liege, Belgium; Unit of Signal Transduction, GIGA-Research, Hospital University of Liege Sart-Tilman, University of Liege, 4000 Liege, Belgium
| | - Emmanuel Dejardin
- Interdisciplinary Cluster of Applied Genoproteomics, GIGA-Research, Hospital University of Liege Sart-Tilman, University of Liege, 4000 Liege, Belgium; Unit of Signal Transduction, GIGA-Research, Hospital University of Liege Sart-Tilman, University of Liege, 4000 Liege, Belgium; Laboratory of Molecular Immunology and Signal Transduction, Hospital University of Liege Sart-Tilman, University of Liege, 4000 Liege, Belgium; and
| | - Daniel Desmecht
- Department of Veterinary Pathology, Fundamental and Applied Research for Animals and Health, University of Liege, 4000 Liege, Belgium
| | - Kateryna Shostak
- Interdisciplinary Cluster of Applied Genoproteomics, GIGA-Research, Hospital University of Liege Sart-Tilman, University of Liege, 4000 Liege, Belgium; Laboratory of Medical Chemistry, Hospital University of Liege Sart-Tilman, University of Liege, 4000 Liege, Belgium; Unit of Signal Transduction, GIGA-Research, Hospital University of Liege Sart-Tilman, University of Liege, 4000 Liege, Belgium
| | - Alain Chariot
- Interdisciplinary Cluster of Applied Genoproteomics, GIGA-Research, Hospital University of Liege Sart-Tilman, University of Liege, 4000 Liege, Belgium; Laboratory of Medical Chemistry, Hospital University of Liege Sart-Tilman, University of Liege, 4000 Liege, Belgium; Unit of Signal Transduction, GIGA-Research, Hospital University of Liege Sart-Tilman, University of Liege, 4000 Liege, Belgium; Walloon Excellence in Life Sciences and Biotechnology, Hospital University of Liege Sart-Tilman, University of Liege, 4000 Liege, Belgium
| |
Collapse
|
18
|
Richters A, Basu D, Engel J, Ercanoglu MS, Balke-Want H, Tesch R, Thomas RK, Rauh D. Identification and further development of potent TBK1 inhibitors. ACS Chem Biol 2015; 10:289-98. [PMID: 25540906 DOI: 10.1021/cb500908d] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
The cytosolic Ser/Thr kinase TBK1 was discovered to be an essential element in the mediation of signals that lead to tumor migration and progression. These findings meet the need for the identification of novel tool compounds and potential therapeutics to gain deeper insights into TBK1 related signaling and its relevance in tumor progression. Herein, we undertake the activity-based screening for unique inhibitors of TBK1 and their subsequent optimization. Initial screening approaches identified a selection of TBK1 inhibitors that were optimized using methods of medicinal chemistry. Variations of the structural characteristics of a representative 2,4,6-substituted pyrimidine scaffold resulted in improved potency. Prospective use as tool compounds or basic contributions to drug design approaches are anticipated for our improved small molecules.
Collapse
Affiliation(s)
- André Richters
- Department
of Chemistry and Chemical Biology, Technical University of Dortmund, Otto-Hahn-Straße 6, 44227 Dortmund, Germany
| | - Debjit Basu
- Department
of Chemistry and Chemical Biology, Technical University of Dortmund, Otto-Hahn-Straße 6, 44227 Dortmund, Germany
| | - Julian Engel
- Department
of Chemistry and Chemical Biology, Technical University of Dortmund, Otto-Hahn-Straße 6, 44227 Dortmund, Germany
| | - Meryem S. Ercanoglu
- Department
of Translational Genomics, University of Cologne, Weyertal 115b, 50931 Cologne, Germany
| | - Hyatt Balke-Want
- Department
of Translational Genomics, University of Cologne, Weyertal 115b, 50931 Cologne, Germany
| | - Roberta Tesch
- Department
of Chemistry and Chemical Biology, Technical University of Dortmund, Otto-Hahn-Straße 6, 44227 Dortmund, Germany
- Programa
de Pós-Graduação em Farmacologia e Química
Medicinal, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro, 21941-901 Brazil
| | - Roman K. Thomas
- Department
of Translational Genomics, University of Cologne, Weyertal 115b, 50931 Cologne, Germany
| | - Daniel Rauh
- Department
of Chemistry and Chemical Biology, Technical University of Dortmund, Otto-Hahn-Straße 6, 44227 Dortmund, Germany
| |
Collapse
|